Compare Incyte Corporation (INCY) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Nano Dimension Ltd - ADR — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Nano Dimension Ltd - ADR trades at $1.56 (market cap $328.52M). The key difference: Incyte Corporation is far larger — about 69.6× Nano Dimension Ltd - ADR's market cap, and Incyte Corporation is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| INCY | NNDM | |
|---|---|---|
Market Cap | $22.85B | $328.52M |
Volume | 1,927,029 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $129.93 | $2.14 |
52-Week Low | $83.80 | $1.21 |
Typical Hold Time | 33 Days | 43 Days |
Enterprise Value | $18.35B | -$76.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Nano Dimension (NNDM) trades at $1.555, showing modest daily gains of 0.32%. The technical picture remains bearish with negative moving average signals, while fundamentals reveal significant challenges including a -135.18% net income margin and persistent cash burn. Recent developments include leadership changes and strategic divestitures aimed at reducing annual cash burn by $25 million, with the MarkForged sale expected to close in late 2026.
Despite trading below book value (P/B 0.68), NNDM faces substantial execution risks amid ongoing losses and negative cash flow. The company's restructuring efforts and asset sales provide potential catalysts, but investors should weigh the high-risk profile against the discounted valuation. Near-term performance hinges on successful cost reduction and revenue stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
